A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of COR388 in Older Healthy Volunteers and Patients With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2018
At a glance
- Drugs COR-388 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Cortexyme
- 05 Nov 2018 Status changed from active, no longer recruiting to completed.
- 24 Oct 2018 Results presented in a Cortexyme media release.
- 07 Sep 2018 Status changed from recruiting to active, no longer recruiting.